Yes. With stem-cell injections, the route changes which tissues are exposed and which complications need attention. A vein infusion is not interchangeable with an injection into a joint, spinal fluid, or the eye. But a local injection does not guarantee that harm stays local: a U.S. outbreak investigation documented bloodstream infection after injections into shoulder joints Mm6750a5.htm.
The cell preparation matters too. The U.S. Food and Drug Administration (FDA) warns that unapproved regenerative products can cause infections, unwanted immune reactions, tumor formation, blindness, and neurological events. Choosing a different injection site does not establish that a product is safe or effective Important patient and consumer information about regenerative medicine therapies.

Vein infusions
An intravenous (IV) infusion introduces the preparation into the circulation. Japan’s Ministry of Health, Labour and Welfare (MHLW) specifically warned in March 2026 that systemic IV administration of certain processed cell preparations can cause serious complications, including potentially fatal pulmonary embolism and abnormal heart rhythms. A pulmonary embolism is a blockage in a lung blood vessel 001673212.pdf.
Do not confuse a private clinic’s cell infusion with established blood-forming stem-cell transplantation. In transplantation for certain cancers and blood disorders, cells given through a vein travel to the bone marrow. The treatment can also involve high-dose chemotherapy or radiation; infection and organ damage are risks of the overall treatment, not simply the needle site. With donor cells, graft-versus-host disease can occur when donor immune cells attack the recipient’s tissues Stem cell transplant.
Joint injections
For an injection into a joint, infection of that joint is a specific concern, but systemic infection is also possible. In a 2018 U.S. investigation, four Florida patients developed joint infections after receiving unapproved umbilical-cord-blood-derived products. Across the wider outbreak, 12 infected patients were identified; all were hospitalized and none died. Testing found bacteria in unopened products. These findings concern particular contaminated products, not a complication rate for every knee or joint injection Mm6750a5.htm.
Spinal-fluid injections
An intrathecal injection places material into the cerebrospinal fluid surrounding the brain and spinal cord. A 2023 case report described bacterial meningitis after a woman with multiple sclerosis received two intrathecal injections at a commercial clinic in Mexico in October 2022. The report described the preparation as donor umbilical-cord stem cells. Her infection required prolonged investigation and treatment; this single case cannot establish the frequency of that complication PMC10370854.
If an intervention is offered for spinal cord injury, ask exactly where the cells would be given. An IV infusion and an injection into spinal fluid are different procedures; evidence for one should not be presented as evidence for the other.
Eye injections
A 2017 case series described three U.S. patients with age-related macular degeneration who received their own fat-derived cell preparations inside both eyes on the same day. Before treatment, visual acuity ranged from 20/30 to 20/200. A year later, it ranged from 20/200 to no light perception. Reported complications included high eye pressure, bleeding, retinal detachment, and lens dislocation PMC5551890.
The authors considered the cell preparations a likely contributor and described same-day treatment of both eyes with the experimental procedure as atypical and unsafe. This is not evidence that routine injections of approved eye medicines carry the same risk. Nor can a three-patient series tell us how often these injuries occur PMC5551890.
Routes compared
| Route | Area exposed | Concerns documented in the sources |
|---|---|---|
| Vein (IV) | Circulation and organs beyond the injection site | Pulmonary embolism and abnormal heart rhythms with certain processed cell preparations; infection and immune reactions are also concerns with unapproved products 001673212.pdfImportant patient and consumer information about regenerative medicine therapies |
| Joint | The treated joint, with possible systemic complications | Joint infection and bloodstream infection after contaminated products Mm6750a5.htm |
| Spinal fluid (intrathecal) | The fluid surrounding the brain and spinal cord | Bacterial meningitis reported after intrathecal cell injections PMC10370854 |
| Inside the eye (intravitreal) | Structures essential for vision | High eye pressure, bleeding, retinal detachment, lens dislocation, and severe vision loss in the three-patient series PMC5551890 |
Can one route be called safest?
Not from these reports. They involve different cell preparations, diagnoses, and clinical settings, rather than a matched comparison of all four routes. The 12 infections in the 2018 investigation are a count of detected cases, not a percentage of everyone treated. Likewise, the eye series has no comparison group. Neither source provides a personal risk estimate for a different procedure Mm6750a5.htmPMC5551890.
If a clinic offers you a knee injection but supplies an IV study, ask for evidence matching the proposed product, diagnosis, dose, and route. Check how many people received that treatment, how long they were followed, and whether the report counted minor reactions as well as hospitalizations. A study reporting no serious events is not a guarantee that none can occur.
Product safety and approval
Changing the route does not correct contaminated manufacturing or make an unproven product effective. FDA’s warning includes processing contamination and unwanted immune responses, even with products collected from a person’s own body. A ClinicalTrials.gov listing or FDA registration is not proof that a product is legally marketed Important patient and consumer information about regenerative medicine therapies.
Japanese safety reports also show why the product and reporting system matter. An MHLW order dated 13 March 2026 described a death after deterioration during administration of autologous fat-derived mesenchymal cells for chronic pain; the cause remained undetermined at the time of the order Newpage_71555. A separate order dated 21 April 2026 described at least five patients who became unwell after treatment under another chronic-pain plan in May 2023, with at least one requiring hospitalization. Required illness reports and investigation had not been carried out while treatment continued. These orders are safety reports, not route-specific complication rates Newpage_72690.
In Japan, submitting a regenerative-medicine provision plan after committee review is different from obtaining marketing approval for a product. Product approval follows a separate review of evidence concerning quality, efficacy, and safety and is granted by MHLW. A plan number alone is not proof of approved efficacy for your condition 001673212.pdf000280722.pdf. The site’s Japan safety overview provides further context; the official sources establish the regulatory distinction.
Questions for your clinician
- What is the exact product, cell source, dose, injection site, and number of sessions?
- Is this an approved product for my condition and route, an authorized clinical trial, or a private service without product approval for this use?
- What safety data match this preparation and procedure, and what follow-up is available for delayed complications?
- How are contamination and batch quality checked, and who manages a serious reaction during treatment or after I return home?
Bottom line
Injection location affects risk, but it does not determine safety on its own. Compare evidence for the exact cells, preparation, diagnosis, and route—not the label “stem-cell therapy.” Local delivery does not eliminate systemic harm, and established blood-forming transplantation should not be used to validate an unrelated clinic injection.
Considering an injection for a specific diagnosis? You can send your records and questions for an initial check of the route, product, and approval status in Japan.
References
- CDC. Infections after receipt of bacterially contaminated umbilical cord blood-derived stem-cell products — United States, 2018. MMWR 2018;67:1397–1399.
- U.S. FDA. Important Patient and Consumer Information About Regenerative Medicine Therapies. Consumer warning dated 3 June 2021; page marked current as of 8 April 2024.
- Japan MHLW. Safety notice for institutions providing regenerative medicine under the Act on the Safety of Regenerative Medicine. 12 March 2026; Japanese PDF.
- National Cancer Institute. Stem Cell Transplants in Cancer Treatment.
- Wolf AB et al. Mycobacterium abscessus Meningitis Associated with Stem Cell Treatment During Medical Tourism. Emerging Infectious Diseases 2023;29:1655–1658.
- Kuriyan AE et al. Vision Loss after Intravitreal Injection of Autologous “Stem Cells” for AMD. New England Journal of Medicine 2017;376:1047–1053.
- Japan MHLW. Emergency order under the Act on the Safety of Regenerative Medicine. 13 March 2026.
- Japan MHLW. Emergency order under the Act on the Safety of Regenerative Medicine. 21 April 2026.
- MHLW, hosted by PMDA. Applications for Marketing Approval of Regenerative Medical Products. Section 1; revised 31 March 2026, provisional English translation May 2026.




